Skip to content
Screener

Hyperfine, Inc. HYPR Deferred Grant Funding Current

Deferred Grant Funding Current at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$5.59M+3.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$5.59M+3.0%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$5.59M+3.0%
Sunrun logo
SunrunRUN
$9M+8.7%
FormFactor logo
FormFactorFORM
$18M0.0%
AstroNova, Inc. logo
AstroNova, Inc.ALOT
$926K-19.1%

Other financials

Income statement

See full
Revenue$3.9M+44.8%
Gross profit$2.0M+49.1%
Operating income-$8.5M+11.7%
Net income-$9.3M-0.8%
EPS (diluted)-$0.09+25.0%

Balance sheet

See full
Cash & equivalents$43.5M+71.0%
Total debt$13.4M+5,536%
Total equity$36.8M+4.6%
Total assets$63.0M+39.3%

Cash flow

See full
Operating cash flow-$7.3M+8.1%
CapEx$30.0K-94.2%
Free cash flow-$7.3M+13.4%

Valuation

See full
Market cap$97.28M+6.8%
Enterprise value$67.24M+2.0%
P/S5.9×-2.6×

Profitability

See full
Gross margin51.4%+5.6pp
Operating margin-203.3%-65.9pp
Net margin-210.8%-62.5pp
FCF margin-166.5%-54.7pp

Returns & leverage

See full
Return on equity-97%+33.2pp
Debt / equity0.4×+0.4×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Hyperfine, Inc. in its filing.

Tagged under the XBRL concept hypr:DeferredGrantFundingCurrent.

The source filing: Hyperfine, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338015
Line itemJune 30, 2026December 31, 2025
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable$2,422$4,051
Deferred grant funding1,306957
Deferred revenue1,6611,544
Due to related parties6150
Accrued expenses and other current liabilities4,1795,130
Total current liabilities9,62911,732

Item 1. Financial Statements

FAQ

What is Hyperfine, Inc.'s deferred grant funding current?
Hyperfine, Inc. (HYPR) reported deferred grant funding current of $1.31M in Q2 2026.
How has Hyperfine, Inc.'s deferred grant funding current changed year-over-year?
Hyperfine, Inc.'s deferred grant funding current increased by 726.6% year-over-year, from $158K to $1.31M.
What is the long-term trend for Hyperfine, Inc.'s deferred grant funding current?
Over 5 years (2020 to 2025), Hyperfine, Inc.'s deferred grant funding current has grown at a -27.9% compound annual growth rate (CAGR), from $4.91M to $957K.
What does deferred grant funding current mean?
Deferred Grant Funding Current as reported by Hyperfine, Inc. Class A Common Stock.

Ask your AI about Hyperfine, Inc.'s deferred grant funding current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude